Oral Contraceptive Use and the Risk of Breast Cancer

Casey, Petra M.; Cerhan, James R.; Pruthi, Sandhya
January 2008
Mayo Clinic Proceedings;Jan2008, Vol. 83 Issue 1, p86
Academic Journal
The clinical impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more than a quarter of a million women are diagnosed as having breast cancer in the United States annually. Substantial changes to OC formulations have been made during the past decade, and this review focuses on recent OC trends and risks and benefits. We also have a better understanding of how estrogen affects breast carcinogenesis; research on this topic is ongoing and has the goal of decreasing breast cancer incidence and mortality.


Related Articles

  • Try switching POP to control irregular bleeding.  // Pulse;6/1/2011, Vol. 71 Issue 20, p7 

    The article cites an updated continuing professional development (CPD) module which suggests that women taking a progestogen-only pill (POP) to switch another POP with a different progestogen of she is having problems with irregular bleeding.

  • Hormone replacement therapy quadruples risk of breast cancers. Mayor, Susan // BMJ: British Medical Journal (International Edition);1/19/2008, Vol. 336 Issue 7636, p116 

    The article reports on U.S. research on breast cancer authored by Christopher Li of the Fred Hutchinson Cancer Research Center that found that postmenopausal women taking combined estrogen and progestin hormone replacement therapy for three years or longer face four times the risk of developing...

  • Factors determining use of oral contraceptive. Chudasama, Rajesh K.; Kavishwar, Abhay B.; Godara, Naresh R.; Moitra, Mohua // Internet Journal of Epidemiology;2009, Vol. 7 Issue 2, p1 

    To evaluate the factors determining use of oral contraceptives in reproductive age group women attending family planning clinic at New Civil Hospital, Surat, present study was conducted during October to December, 2007. After taking informed consent, 235 women were interviewed using pretested...

  • Contraception update: part 2 Progestogen-only pill. Kraszewski, Sarah // Practice Nurse;5/9/2008, Vol. 35 Issue 9, p20 

    The article discusses the progestogen-only pill (POP) as a contraceptive choice for women. POP contains the hormone progestogen and is known colloquially as the mini-pill. It is less popular than the combined oral contraceptive pill (COCP), but it is a useful option for women in whom an...

  • Progesterone receptor modulator eyed for EC.  // Contraceptive Technology Update;Feb2007, Vol. 28 Issue 2, p16 

    Scientists are looking at CDB-2914, a new progesterone receptor modulator (PRM), that may provide emergency contraception (EC) in a single tablet with one-time dosing. • Results of a new study suggest that CDB-2914 is at least as effective as levonorgestrel in preventing pregnancies after...

  • Plan B emergency contraception now available.  // New York Amsterdam News;11/25/99, Vol. 90 Issue 48, p16 

    Informs on Planned Parenthood of New York City's announcement of the availability of Plan B, the progestin-only emergency contraceptive product approved by the United States Food and Drug Administration. How Plan B works; Citing of the role of pharmacists and physicians in informing clients...

  • HNF1B and Endometrial Cancer Risk: Results from the PAGE study. Setiawan, Veronica Wendy; Haessler, Jeffrey; Schumacher, Fredrick; Cote, Michele L.; Deelman, Ewa; Fesinmeyer, Megan D.; Henderson, Brian E.; Jackson, Rebecca D.; V�ckler, Jens-S; Wilkens, Lynne R.; Yasmeen, Shagufta; Haiman, Christopher A.; Peters, Ulrike; Le Marchand, Lo�c; Kooperberg, Charles // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    We examined the association between HNF1B variants identified in a recent genome-wide association study and endometrial cancer in two large case-control studies nested in prospective cohorts: the Multiethnic Cohort Study (MEC) and the Women's Health Initiative (WHI) as part of the Population...

  • THE AUTHORS REPLY. Rosenberg, Lynn; Yuqing Zhang; Coogan, Patricia F.; Strom, Brian L.; Palmer, Julie R. // American Journal of Epidemiology;Sep2009, Vol. 170 Issue 6, p803 

    The article presents a response to a commentary on the paper "A Case-Control Study of Oral Contraceptive Use and Incident Breast Cancer." The use of less than 1 year of oral contraceptive use as the reference category in the analysis of the association between contraceptive use and breast cancer...

  • Increased Risk for Invasive Breast Cancer Associated with Hormonal Therapy: A Nation-Wide Random Sample of 65,723 Women Followed from 1997 to 2008. Jung-Nien Lai; Chien-Tung Wu; Pau-Chung Chen; Chiun-Sheng Huang; Song-Nan Chow; Jung- Der Wang // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: Hormonal therapy (HT) either estrogen alone (E-alone) or estrogen plus progesterone (E+P) appears to increase the risk for breast cancer in Western countries. However, limited information is available on the association between HT and breast cancer in Asian women characterized mainly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics